Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -5 of 5 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 3/1/1996


1.		Phase II Randomized, Double-Blind Study of RMP-7 (A Bradykinin Analogue) plus CBDCA vs CBDCA/Placebo for Recurrent Malignant Glioma (Summary Last Modified 03/96)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				ALK-01-017 DFCI-95066, NCI-V95-0789

Last Modified: 8/1/1996


2.		Phase II Study of RMP-7 (a Bradykinin Analogue) plus CBDCA Administered Intra-Arterially for Recurrent Malignant Glioma (Summary Last Modified 08/96)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				YALE-HIC-8729 NCI-V96-0884

Last Modified: 5/18/2007 First Published: 5/1/1998


3.		Phase II Study of Lobradimil and Carboplatin in Patients With Recurrent or Refractory Childhood Brain Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				21 and under at diagnosis				NCI				NCI-98-C-0074H CCG-09716, ALK-01-041, NCI-T98-0011, COG-C09716, T98-0011, NCT00019422

Last Modified: 5/8/2006


4.		Phase I Study of RMP-7 (a Bradykinin Analogue) and Carboplatin for Refractory Childhood Brain Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				21 and under				NCI, Pharmaceutical / Industry				ALK-01-036 NCI-96-C-0068C

Last Modified: 10/31/2007 First Published: 5/1/2000


5.		Phase I Study of Lobradimil Plus Carboplatin With Radiotherapy in Patients With Newly Diagnosed Brain Stem Gliomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Temporarily closed				3 to 21				NCI				COG-ADVL0012 CCG-ADVL0012, ALK-01-042, CCG-09802, NCT00005602, ADVL00012

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute